JNJ-87890387 for Solid Tumors

"Based on the assessment from our team at Power, we assign a safety rating of 1 to JNJ-87890387. This is due to it being in Phase 1 trial where there is limited data supporting both its safety and effectiveness."

"Indeed, the data provided on clinicaltrials.gov clearly indicates that this ongoing clinical trial is actively seeking eligible participants. The study was initially posted on December 29th, 2023 and recently updated on December 12th, 2023. In total, the trial aims to enroll 140 individuals from a single designated site or location."

"The primary objective of this clinical trial, assessed within the first 21 days after the initial dose in both Part 1 and Part 2, is to determine the number of participants experiencing adverse events (AEs) categorized by severity. Secondary objectives include evaluating the presence of anti-JNJ-87890387 antibodies among participants, calculating the area under the curve (AUC[t1-t2]) for JNJ-87890387 concentrations over time from t1 to t2, and reporting on the accumulation ratio of JNJ-87890387 using Cmax or AUC values after multiple doses compared to those after the first dose."

"Indeed, the details available on clinicaltrials.gov confirm that this study is actively seeking participants. The trial was initially posted on December 29, 2023, and most recently updated on December 12, 2023. To complete the study successfully, a total of 140 individuals are being sought at one designated site."